联邦学习预测三阴性乳腺癌新辅助化疗的组织学反应
本研究利用全切片图像和临床信息,通过联邦学习在多中心真实世界数据上训练机器学习模型,以在诊断时预测早期三阴性乳腺癌患者对新辅助化疗的组织学反应。结果显示,基于全切片图像的本地模型可预测反应,而协作训练进一步提升了性能,与当前依赖耗时专家标注的最佳方法相当。
要点
- 基于全切片图像的本地机器学习模型可预测三阴性乳腺癌新辅助化疗的组织学反应。
- 联邦学习协作训练进一步提升模型性能,与依赖耗时专家标注的最佳方法相当。
- 该概念验证研究在保护数据隐私前提下利用多中心真实世界数据,为未来生物标志物发现铺路。
核心结论
- 基于全切片图像的本地机器学习模型可预测新辅助化疗反应,联邦学习协作训练进一步提升性能,与依赖耗时专家标注的最佳方法相当。
研究设计与样本
- 多中心三阴性乳腺癌研究,采用联邦学习训练机器学习模型,患者数据保留在医院防火墙后,利用全切片图像和临床信息在诊断时预测新辅助化疗的组织学反应。
主要发现
- 基于全切片图像的本地机器学习模型可预测新辅助化疗反应。
- 联邦学习协作训练进一步改善机器学习模型性能,与依赖耗时专家标注的最佳当前方法相当。
- 机器学习模型具有可解释性,对特定组织学模式敏感。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Triple-negative breast cancer (TNBC) is a rare cancer, characterized by high metastatic potential and poor prognosis, and has limited treatment options. The current standard of care in nonmetastatic settings is neoadjuvant chemotherapy (NACT), but treatment efficacy varies substantially across patients. This heterogeneity is still poorly understood, partly due to the paucity of curated TNBC data. Here we investigate the use of machine learning (ML) leveraging whole-slide images and clinical information to predict, at diagnosis, the histological response to NACT for early TNBC women patients. To overcome the biases of small-scale studies while respecting data privacy, we conducted a multicentric TNBC study using federated learning, in which patient data remain secured behind hospitals' firewalls. We show that local ML models relying on whole-slide images can predict response to NACT but that collaborative training of ML models further improves performance, on par with the best current approaches in which ML models are trained using time-consuming expert annotations. Our ML model is interpretable and is sensitive to specific histological patterns. This proof of concept study, in which federated learning is applied to real-world datasets, paves the way for future biomarker discovery using unprecedentedly large datasets.
引用
- Ogier du Terrail J, Leopold A, Joly C, et al. Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer. Nat Med. 2023. PMID: 36658418. doi:10.1038/s41591-022-02155-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。